Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Generation of monoclonal antibodies and development of an immunofluorometric assay for the detection of CUZD1 in tissues and biological fluids.

Farkona S, Soosaipillai A, Filippou P, Korbakis D, Serra S, Rückert F, Diamandis EP, Blasutig IM.

Clin Biochem. 2017 Dec;50(18):1168-1174. doi: 10.1016/j.clinbiochem.2017.07.012. Epub 2017 Jul 23.

PMID:
28746862
2.

Biochemical and functional characterization of the human tissue kallikrein 9.

Filippou PS, Farkona S, Brinc D, Yu Y, Prassas I, Diamandis EP.

Biochem J. 2017 Jul 6;474(14):2417-2433. doi: 10.1042/BCJ20170174.

PMID:
28559305
3.

The Phoenix Rises: The Rebirth of Cancer Immunotherapy.

Blasutig IM, Farkona S, Buchbinder EI, Luke JJ, Sharma P, Sznol M.

Clin Chem. 2017 Jul;63(7):1190-1195. doi: 10.1373/clinchem.2016.267849. Epub 2017 May 17. No abstract available.

4.

Novel immunoassays for detection of CUZD1 autoantibodies in serum of patients with inflammatory bowel diseases.

Farkona S, Soosaipillai A, Filippou P, Liaskos C, Bogdanos DP, Diamandis EP, Blasutig IM.

Clin Chem Lab Med. 2017 Aug 28;55(10):1574-1581. doi: 10.1515/cclm-2016-1120.

PMID:
28343172
5.

A new enzyme-linked immunosorbent assay (ELISA) for human free and bound kallikrein 9.

Filippou P, Korbakis D, Farkona S, Soosaipillai A, Karakosta T, Diamandis EP.

Clin Proteomics. 2017 Jan 17;14:4. doi: 10.1186/s12014-017-9140-6. eCollection 2017.

6.

Cancer immunotherapy: the beginning of the end of cancer?

Farkona S, Diamandis EP, Blasutig IM.

BMC Med. 2016 May 5;14:73. doi: 10.1186/s12916-016-0623-5. Review.

7.

PIK3CA mutational status in circulating tumor cells can change during disease recurrence or progression in patients with breast cancer.

Markou A, Farkona S, Schiza C, Efstathiou T, Kounelis S, Malamos N, Georgoulias V, Lianidou E.

Clin Cancer Res. 2014 Nov 15;20(22):5823-34. doi: 10.1158/1078-0432.CCR-14-0149.

8.

False biomarker discovery due to reactivity of a commercial ELISA for CUZD1 with cancer antigen CA125.

Prassas I, Brinc D, Farkona S, Leung F, Dimitromanolakis A, Chrystoja CC, Brand R, Kulasingam V, Blasutig IM, Diamandis EP.

Clin Chem. 2014 Feb;60(2):381-8. doi: 10.1373/clinchem.2013.215236. Epub 2013 Oct 4.

Supplemental Content

Loading ...
Support Center